Dr. David Rabin MD, PhD is the chief innovation officer, co-founder and co-inventor at Apollo Neuroscience Inc. In his role, Dr. Rabin is developing Apollo Neuroscience’s IP portfolio and running clinical trials of the Apollo technology, the first scientifically-validated wearable system to improve focus, sleep and access to meditative states by delivering layered vibrations to the skin. Dr. Rabin is a board-certified psychiatrist, translational neuroscientist, inventor and has been studying the impact of chronic stress in humans for more than 10 years. He has specifically focused his research on the clinical translation of non-invasive therapies that improve mood, focus, sleep and quality of life in treatment-resistant illnesses. Dr. Rabin received his MD in medicine and a PhD in neuroscience from Albany Medical College and trained in psychiatry at Western Psychiatric Institute & Clinic at the University of Pittsburgh Medical Center.
Dr. Rabin organized the world’s largest controlled study of psychedelic medicines in collaboration with colleagues at Yale, the University of Southern California, Mt. Sinai, I’Dor, Modern Spirit, and MAPS (Multidisciplinary Association of Psychedelic Studies) to determine the mechanisms of the dramatic therapeutic benefits observed following psychedelic-assisted psychotherapy in treatment-resistant mental illness. Biological specimens are being collected from the first cohort of patients diagnosed with treatment-resistant PTSD in the MAPS FDA phase 3 double-blind randomized placebo-controlled crossover trial that began in 2019.
Dr. Rabin is also the founder and executive director of the Board of Medicine, a nonprofit charity focused on improving the safety and effectiveness of medication-based treatments for patients and healthcare providers. Dr. Rabin built and led a team of expert physicians and scientists to spearhead the development of the world’s first evidence-based peer-reviewed clinical guidelines for the safe use of medical cannabis and other complementary and alternative medicines. The Board of Medicine uses these guidelines to train and certify healthcare providers and industry partners, as well as to provide quality control standards for natural and unregulated medicines to support the community goals of high-quality clinical research and harm-reduction.
Dr. Rabin continues his clinical psychiatry practice providing psychiatric treatment as well as psychotherapy services to his clients and patients in California and Pennsylvania.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | RSS